Nuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung.
Leukotriene A4 (LTA4) hydrolase catalyzes the final step in leukotriene B4 (LTB4) synthesis. In addition to its role in LTB4 synthesis, the enzyme possesses aminopeptidase activity. In this study, we sought to define the subcellular distribution of LTA4 hydrolase in alveolar epithelial cells, which lack 5-lipoxygenase and do not synthesize LTA4. Immunohistochemical staining localized LTA4 hydrolase in the nucleus of type II but not type I alveolar epithelial cells of normal mouse, human, and rat lungs. Nuclear localization of LTA4 hydrolase was also demonstrated in proliferating type II-like A549 cells. The apparent redistribution of LTA4 hydrolase from the nucleus to the cytoplasm during type II-to-type I cell differentiation in vivo was recapitulated in vitro. Surprisingly, this change in localization of LTA4 hydrolase did not affect the capacity of isolated cells to convert LTA4 to LTB4. However, proliferation of A549 cells was inhibited by the aminopeptidase inhibitor bestatin. Nuclear accumulation of LTA4 hydrolase was also conspicuous in epithelial cells during alveolar repair following bleomycin-induced acute lung injury in mice, as well as in hyperplastic type II cells associated with fibrotic lung tissues from patients with idiopathic pulmonary fibrosis. These results show for the first time that LTA4 hydrolase can be accumulated in the nucleus of type II alveolar epithelial cells and that redistribution of the enzyme to the cytoplasm occurs with differentiation to the type I phenotype. Furthermore, the aminopeptidase activity of LTA4 hydrolase within the nucleus may play a role in promoting epithelial cell growth.
Brock
Thomas G
TG
Dept. of Internal Medicine, Univ. of Michigan, 6301 MSRB III, Ann Arbor, MI 48109-0642, USA. brocko@umich.edu
Lee
Young-Jik
YJ
Maydanski
Elana
E
Marburger
Tessa L
TL
Luo
Ming
M
Paine
Robert
R
Peters-Golden
Marc
M
D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001761:Bleomycin / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002467:Cell Nucleus / Q000201:enzymology*; D049109:Cell Proliferation / Q000187:drug effects; D003593:Cytoplasm / Q000201:enzymology; D004851:Epoxide Hydrolases / Q000378:metabolism*; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D017572:Leukotriene A4 / Q000378:metabolism; D007975:Leukotriene B4 / Q000378:metabolism; D008297:Male; D051379:Mice; D011480:Protease Inhibitors / Q000494:pharmacology; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000201:enzymology; D011658:Pulmonary Fibrosis / Q000201:enzymology* / Q000473:pathology; D051381:Rats; D011916:Rats, Inbred F344; D020545:Respiratory Mucosa / Q000187:drug effects / Q000201:enzymology*; D013347:Subcellular Fractions / Q000378:metabolism*; D014018:Tissue Distribution
D000903:Antibiotics, Antineoplastic; D017572:Leukotriene A4; D011480:Protease Inhibitors; D001761:Bleomycin; D007975:Leukotriene B4; D004851:Epoxide Hydrolases; D000626:Aminopeptidases; D007930:Leucine; C012211:ubenimex; C043134:leukotriene A4 hydrolase